New insider activity at Trevi Therapeutics ( (TRVI) ) has taken place on March 27, 2025.
CSO Thomas Sciascia recently sold 2,631 shares of Trevi Therapeutics stock, amounting to a total transaction value of $17,364.
Recent Updates on TRVI stock
Trevi Therapeutics has recently experienced significant developments, particularly with its lead drug, Haduvio. The company reported positive clinical outcomes from the Phase 2a RIVER trial, which demonstrated a substantial reduction in cough frequency among RCC patients. This success has bolstered confidence in the drug’s potential and contributed to an increase in the firm’s price target. The analyst’s decision to raise the price target was influenced by the positive trial data, which de-risks the upcoming Phase 2b IPF CC CORAL study. Despite these clinical advancements, Trevi faces financial challenges, with increased net losses and R&D expenses due to ongoing clinical trials. However, the company’s strong cash position, with a runway extending into the second half of 2026, supports its continued investment in drug development.
More about Trevi Therapeutics
YTD Price Performance: 51.61%
Average Trading Volume: 1,933,102
Technical Sentiment Signal: Sell
Current Market Cap: $639.1M